Reuters: Regulatory News: US FDA advisers rebuff J&J/Bayer Xarelto heart drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

US FDA advisers rebuff J&J/Bayer Xarelto heart drug May 23rd 2012, 20:23 SILVER SPRING, Md. | Wed May 23, 2012 4:23pm EDT SILVER SPRING, Md. May 23 (Reuters) - A U.S. advisory panel rebuffed Johnson & Johnson's blood thinner, meant to reduce the risk of new heart attacks and strokes in people with heart problems. A panel of outside experts to the Food and Drug Administration voted 6 to 4 on Wednesday that Xarelto should not be approved for people with acute coronary syndrome. J&J developed the drug in partnership with German drugmaker Bayer AG . The FDA usually follows panel recommendations, although it is not required to, and a final decision is expected by the end of June.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions